Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties

Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties Inhibitors of cyclic AMP phosphodiesterase. 1. Analogs of cilostamide and anagrelide Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity Identification of a Promising Drug Candidate for the Treatment of Type 2 Diabetes Based on a P2Y₁ Receptor Agonist Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones - inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogs of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline Lipophilic Modifications to Dinucleoside Polyphosphates and Nucleotides that Confer Antagonist Properties at the Platelet P2Y₁₂ Receptor